Winning the same industry peer award two years running is harder than winning it once, and that’s the number worth noting: Medpace has taken the CRO slot in the SCRS Eagle Award for 2026, repeating its 2025 win. The recognition carries more weight than a typical trade group citation because the scores come directly from sites. Nearly 2,000 research sites across the globe rated their CRO and sponsor partners through the annual SCRS survey, covering everything from budgeting approach and contract language to payment speed and technology use.
That voting base matters for how the result should be read. Sites are the operational bottleneck in most trials: slow start-up, payment disputes, and poor communication at the site level delay enrollment and, eventually, data. A CRO that consistently ranks well across those specific categories in a large, global site survey has something more durable than a curated reference list. The SCRS program has run since 2009 and names one CRO and one sponsor winner each year, so the field is not partitioned by size or therapeutic area.
The survey categories are worth noting individually, because they map directly to where CRO-site friction tends to accumulate: business development practices, budget negotiation style, contract language, payment timelines, communication responsiveness, start-up efficiency, community access for participants, and technology integration. Medpace’s repeat win suggests the site community sees consistent performance across that range, not strength in one or two areas that might mask problems elsewhere.
The award was presented October 17 at the SCRS Global Site Solutions Summit Eagle Award Gala. For clinical operations teams evaluating CRO partners, the most concrete signal here is the repeat: a single Eagle Award can reflect a strong year; two consecutive wins in the same program, scored by the same global site community, is harder to attribute to timing. The category to watch is payment process and contract language, where site dissatisfaction typically surfaces first when CRO-sponsor relationships are under pressure.
Source link: https://www.medpace.com/blog/medpace-recognized-as-cro-recipient-of-the-2026-scrs-eagle-award/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
